Adjust Text Size:
Browse Clinical Trials
Join the Email List
Sign up for our email bulletin
Participant Stories
“I participate because it is the right thing to do, for myself, for my children, and for the millions of people who have Parkinson’s disease. Without participation there will be no cure.” –Mike, Diagnosed 7 years
Recently Diagnosed with Parkinson's Disease?
If you have recently been diagnosed with Parkinson’s disease (PD) understanding the disease, and learning about the resources available to you, are good first steps.
Mapping Mood in Parkinson's Disease (MOOD D)
Official Study Title: Mapping Mood in the Subthalamic Nucleus in Parkinson's Disease Parkinson's DiseaseA chronic, slowly progressive disease of the nervous system characterized by the combination of tremor, rigidity, bradykinesia and stooped posture, among other symptoms. (PD) (MOOD D)
Sponsor: Washington University School of Medicine
Clinicaltrials.gov ID: NCT00847431
Study ID: 08-0354, RO1 NS058797
Summary
The goal of this study is to determine the vulnerability of mood-related neurocircuitry in Parkinson’s disease (PD) using deep brain stimulation Deep Brain Stimulation (DBS)Procedure in which a small, surgically implanted, battery-operated medical device delivers electrical stimulation, and "turns-off" brain regions that produce Parkinson’s symptoms. of the subthalamic nucleus (STN DBS). Depression and anxiety are highly prevalent (25 to 40 percent) in individuals with PD and are the main cause of decreased quality of life. Treatment with STN DBS has significant motor benefits for many people with PD. However, STN DBS can have unintended consequences on mood, perhaps due in part to the location of the active contact(s). So, understanding the neural circuits and variables for the development of depression or anxiety in PD is an important area of research with significant clinical ClinicalDealing with or based on observation and treatment of people, as opposed to basic science carried out in the laboratory or in animals. implications.
The investigators will use STN DBS (and a validated method for locating the site of contacts within the STN) to address questions about the neural circuitry underlying acute and chronic mood dysfunction in PD. In addition to the direct clinical relevance for people PD both with and without DBS, a better understanding of the neural circuitry involved in mood changes may provide useful information for others as well.
Study Phase
Not Applicable
What is a study phase?
Symptoms Addressed: Study does not address symptoms
Study does not address symptoms
Time Commitment
- More than six months
- Time commitment is two years but only a maximum of 5 study visits in that time.
Eligibility
- Minimum Age: 40
- Gender(s) Accepted: Either
Inclusion Criteria
- Diagnosis of PD
- Age 40 or older
- DBS STN Surgery in past 2 to 36 months
- Ability to tolerate turning off stimulators
- Ability to read and comprehend questions
- English speaking
Exclusion Criteria
- Other severe complications post surgery: stroke, seizure, major loss of consciousness, other brain trauma/surgery, or head injuries(i.e. near drowning), encephalitis, or hydrocephalus, blindness, deafness
- Clinically determined dementia DementiaA decline in higher-level brain functions, such as memory, reasoning and personality.
Enrollment
Expected Enrollment: 103 (US)
Date Enrollment Began: Oct 2008
Date Enrollment Ends: Dec 2013
Last Updated Date: Sep 28 2009
Trial Post Date: Jul 08 2009
Website: http://clinicaltrials.gov/ct2/show/NCT00847431?term=NCT00847431&rank=1
Primary Contacts and Locations
Missouri
- Samantha Blankenship, MSW
Washington University School of Medicine
blankenships@npg.wustl.edu
Phone: (314) 362-6514
St. Louis, MO 63110
USA
Local Contacts and Locations
Ohio
- Maureen Gartner, RN, M.Ed.
University of Cincinnati, Movement Disorder Center
gartnem@ucmail.uc.edu
Phone: (513) 558-0018
Cincinnati, OH 45267
USA
